Beyond Air, Inc. (NASDAQ:XAIR – Get Free Report) CEO Robert Scott Goodman acquired 34,722 shares of Beyond Air stock in a transaction dated Wednesday, July 29th. The shares were acquired at an average price of $5.76 per share, with a total value of $199,998.72. Following the completion of the purchase, the chief executive officer owned 34,822 shares in the company, valued at approximately $200,574.72. The trade was a 34,722.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
Beyond Air Price Performance
Shares of NASDAQ XAIR opened at $5.28 on Friday. The stock has a market capitalization of $3.80 million, a price-to-earnings ratio of -0.06 and a beta of 0.22. The business has a 50-day moving average of $7.69 and a 200-day moving average of $14.21. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.80 and a quick ratio of 3.59. Beyond Air, Inc. has a fifty-two week low of $5.02 and a fifty-two week high of $95.60.
Beyond Air (NASDAQ:XAIR – Get Free Report) last released its earnings results on Friday, June 26th. The company reported ($15.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($11.33) by ($4.07). Beyond Air had a negative net margin of 432.99% and a negative return on equity of 350.00%. The company had revenue of $1.91 million during the quarter, compared to analyst estimates of $2.30 million.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Beyond Air in a research note on Tuesday, July 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Beyond Air has a consensus rating of “Hold” and an average target price of $200.00.
Get Our Latest Research Report on XAIR
Beyond Air Company Profile
Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.
The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.
Read More
- Five stocks we like better than Beyond Air
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.
